NASDAQ:EDIT

Editas Medicine Stock Insider Trading

etoro logo Buy EDIT
*Your capital is at risk
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026

Editas Medicine Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 71.56. In total, the insiders bought 6.27M and sold 234.06K EDIT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
71.56
Buy 6.27M shares
Sell 234.06K shares
54% Buy Activity
Weak Negative Correlation
Buy Signal Medium Confidence
Mar 12, 2026

Analysis Breakdown:

  • Strongly supported by a very high Insider Power Score of 71.56.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Mar 12, 2026
Buy
Stock Option (right to buy)
A-Award
O'neill Gilmore Neil
CEO
CEO / President 1 015 200
Value: $2.58M
Mar 12, 2026
Buy
Stock Option (right to buy)
A-Award
Parison Amy
SVP, Chief Financial Officer
C-Suite Officer 292 856
Value: $743.9K
Mar 12, 2026
Buy
Stock Option (right to buy)
A-Award
Burkly Linda
EVP, Chief Scientific Officer
Officer 292 856
Value: $743.9K
Mar 03, 2026
Sell
Common Stock
S-Sale
O'neill Gilmore Neil
CEO
CEO / President 5 394
Value: $10.9K
Mar 03, 2026
Sell
Common Stock
S-Sale
Parison Amy
SVP, Chief Financial Officer
C-Suite Officer 474
Value: $957
Mar 03, 2026
Sell
Common Stock
S-Sale
Burkly Linda
EVP, Chief Scientific Officer
Officer 749
Value: $2K
Dec 03, 2025
Sell
Common Stock
S-Sale
Burkly Linda
EVP, Chief Scientific Officer
Officer 713
Value: $2K
Dec 03, 2025
Sell
Common Stock
S-Sale
O'neill Gilmore Neil
CEO
CEO / President 5 603
Value: $12.1K
Dec 03, 2025
Sell
Common Stock
S-Sale
Parison Amy
SVP, Chief Financial Officer
C-Suite Officer 461
Value: $993
Sep 03, 2025
Sell
Common Stock
S-Sale
Burkly Linda
EVP, Chief Scientific Officer
Officer 710
Value: $2K
Sep 03, 2025
Sell
Common Stock
S-Sale
Parison Amy
SVP, Chief Financial Officer
C-Suite Officer 458
Value: $1K
Sep 03, 2025
Sell
Common Stock
S-Sale
O'neill Gilmore Neil
CEO
CEO / President 5 592
Value: $14.5K
Sep 03, 2025
Sell
Common Stock
S-Sale
O'neill Gilmore Neil
CEO
CEO / President 5 592
Value: $14.5K
Sep 03, 2025
Sell
Common Stock
S-Sale
Parison Amy
SVP, Chief Financial Officer
C-Suite Officer 458
Value: $1K
Sep 03, 2025
Sell
Common Stock
S-Sale
Burkly Linda
EVP, Chief Scientific Officer
Officer 710
Value: $2K
Aug 07, 2025
Sell
Common Stock
S-Sale
Parison Amy
SVP, Chief Financial Officer
C-Suite Officer 679
Value: $2K
Aug 07, 2025
Sell
Common Stock
S-Sale
Parison Amy
SVP, Chief Financial Officer
C-Suite Officer 679
Value: $2K
Jul 31, 2025
Sell
Common Stock
S-Sale
Burkly Linda
EVP, Chief Scientific Officer
Officer 5 121
Value: $12.8K
Jul 31, 2025
Sell
Common Stock
S-Sale
Burkly Linda
EVP, Chief Scientific Officer
Officer 5 121
Value: $12.8K
Jun 06, 2025
Buy
Stock Option (right to buy)
A-Award
Hopfield Jessica
Director
Director 37 500
Value: $71.6K
Jun 06, 2025
Buy
Stock Option (right to buy)
A-Award
Scadden David
Director
Director 37 500
Value: $71.6K
Jun 06, 2025
Buy
Stock Option (right to buy)
A-Award
Levy Elliott M.
Director
Director 37 500
Value: $71.6K
Jun 06, 2025
Buy
Stock Option (right to buy)
A-Award
Connaughton Bernadette
Director
Director 37 500
Value: $71.6K
Jun 06, 2025
Buy
Stock Option (right to buy)
A-Award
Hirsch Andrew
Director
Director 37 500
Value: $71.6K
Jun 06, 2025
Buy
Stock Option (right to buy)
A-Award
Hirsch Andrew
Director
Director 37 500
Value: $71.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT EDITAS MEDICINE, INC
Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, whic...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE